SCHEMBL7439619

SCHEMBL7439619

O=C(O)CCC(=O)OC(Cl)C(Cl)Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.41
EGLN1 Q9GZT9 4/20 0.41
ALKBH5 Q6P6C2 1/20 0.41
SUCNR1 Q9BXA5 1/20 0.41
KDM2A Q9Y2K7 5/20 0.40
KDM5C P41229 3/20 0.40
PHF8 Q9UPP1 3/20 0.40
KDM6B O15054 2/20 0.40
FOLH1 Q04609 2/20 0.33
SLC15A2 Q16348 1/20 0.33
MAPK1 P28482 1/20 0.33
SLC13A3 Q8WWT9 1/20 0.33
OR51E2 Q9H255 1/20 0.33
TSHR P16473 2/20 0.32
SLC22A6 Q4U2R8 1/20 0.32
KDM4E B2RXH2 2/20 0.31
GABRR1 P24046 1/20 0.31
NFKB1 P19838 1/20 0.31
PMP22 Q01453 1/20 0.31
TET2 Q6N021 3/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15270647 0.81 LMNA (0.45) LMNAEGLN1ALKBH5SUCNR1KDM2A
SCHEMBL8528906 0.80 TSHR (0.56) LMNATSHRKDM4EALDH1A1
SCHEMBL14661595 0.77 EGLN1 (0.45) LMNAEGLN1ALKBH5SUCNR1KDM2A
SCHEMBL733970 0.77 ALDH1A1 (0.48) LMNAMAPK1TSHRALDH1A1
SCHEMBL9095817 0.74 LMNA (0.52) LMNAMAPK1TSHRALDH1A1
SCHEMBL15270649 0.74 LMNA (0.36) LMNAEGLN1ALKBH5SUCNR1KDM2A
SCHEMBL2171703 0.73 TSHR (0.32) TSHR
SCHEMBL8154447 0.72 LMNA (0.60) LMNAMAPK1TSHRALDH1A1
SCHEMBL29637404 0.72 EGLN1 (0.41) LMNAEGLN1ALKBH5SUCNR1KDM2A
SCHEMBL2063826 0.71 TRPA1 (0.37) TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1285747-A Combination therapy for the treatment of AIDS MERCK & CO INC (US) 2001-02-28 CN disclosed
US-5733907-A Prodrugs of an inhibitor of HIV protease MERCK & CO., INC. (US) 1998-03-31 US disclosed
EP-0806957-A1 COMBINATION THERAPY FOR HIV INFECTION USING THE HIV PROTEASE INHIBITOR INDINAVIR ADN THE REVERSE TRANSCRIPTASE INHIBITOR 3TC, OPTIONALLY TOGETHER WITH AZT, DDI OR DDC Merck & Co., Inc. (US) 1997-11-19 EP disclosed
EP-0767664-A2 COMBINATION THERAPY FOR HIV INFECTION MERCK & CO. INC. (US) 1997-04-16 EP disclosed
EP-0729467-A1 PRODRUGS OF AN INHIBITOR OF HIV PROTEASE MERCK & CO. INC. (US) 1996-09-04 EP disclosed
WO-1996023509-A1 COMBINATION THERAPY FOR HIV INFECTION USING THE HIV PROTEASE INHIBITOR INDINAVIR AND THE REVERSE TRANSCRIPTASE INHIBITOR 3TC, OPTIONALLY TOGETHER WITH AZT, DDI OR DDC MERCK & CO., INC. (US) 1996-08-08 WO disclosed
WO-1996000068-A2 COMBINATION THERAPY FOR HIV INFECTION MERCK & CO., INC. (US) 1996-01-04 WO disclosed
WO-1995014016-A1 PRODRUGS OF AN INHIBITOR OF HIV PROTEASE MERCK & CO., INC. (US) 1995-05-26 WO disclosed